In a retrospective study, patients with advanced fibrosis, particularly those with cirrhosis, had a significant risk for hepatic decompensation within a relatively short period.
As the pace of drug development for hepatitis C virus (HCV) infection accelerates, physicians and their patients are faced with the question of whether to treat with current regimens or wait until better agents become available. To assess the risk of waiting, investigators in Spain examined the likelihood of liver decompensation among HIV/HCV-coinfected patients with advanced fibrosis.
In a retrospective analysis involving 892 HIV/HCV-coinfected patients, liver biopsy or liver stiffness measurement (LSM) by hepatic transient elastography was used to diagnose advanced fibrosis (stage 3 or 4 on biopsy; pre-cirrhosis or cirrhosis on LSM). Liver decompensation was defined as development of spontaneous bacterial peritonitis, portal hypertensive g…
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)